RespirAI Medical News
2 articles
growth-positive
COPD flareups could be predicted via smartwatch - ISRAEL21c
RespirAI, a Tel Aviv-based company, has developed an AI algorithm to predict COPD flareups using data from wearable devices. This innovation aims to address the unmet need for monitoring pulmonary issues like COPD, which affects millions worldwide. The company is conducting clinical trials in Israel and plans to launch its product by 2026. RespirAI has raised $2 million, primarily from eHealth Ventures, and has partnered with the Mayo Clinic to develop a platform for monitoring COPD. Despite challenges posed by the conflict in Gaza, RespirAI continues to advance its technology, aiming to improve patient outcomes and reduce healthcare costs.
InvestmentPartners
growth-positive
RespirAI prepares to set the “smoker’s disease” alight with new digital health platform | CTech
RespirAI, a digital health company, has raised a total of $1.1 million to develop an AI-based platform for real-time monitoring of respiratory conditions, particularly COPD. The company aims to address the unmet need for accurate disease status assessment and prediction of exacerbations in chronic pulmonary diseases. The funds will be used for advancing clinical trials, regulatory approvals, and market preparation. RespirAIs platform uses FDA-approved sensors and a patented AI algorithm to provide comprehensive monitoring and personalized insights, empowering patients and healthcare providers. The product is expected to launch in 2026, targeting COPD patients and healthcare payers seeking remote monitoring solutions.
Investment
